Key takeaways:CND Life Sciences completed a growth financing round led by S-Curve Partners to scale its neurodiagnostics platform. The funds will expand the Syn-One Test, which detects abnormal alpha-synuclein to aid in diagnosing conditions like REM sleep behavior disorder. CND is the developer of the Syn-One Test, a commercially available skin biopsy-based laboratory-developed test designed to detect abnormal, or phosphorylated, alpha-synuclein and other pathological markers. Proceeds from the financing will support sustained growth of the Syn-One platform, expansion of commercial initiatives, product innovation, and strategic partnerships. “This financing gives us the flexibility to invest in innovation, expand access to the Syn-One platform, and strengthen our pharmaceutical and research relationships.”